Treats T. vaginalis infection in females and males. ANDA 209794, held by Cadila Pharmaceuticals. Metronidazole.
As of Nov 21, 2026, ANDA 209794 (Metronidazole), held by Cadila Pharmaceuticals, was first approved by FDA on Dec 12, 2017, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Symptomatic Trichomoniasis. Metronidazole tablets USP is indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets USP is indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 12, 2017 | Original application | Approved | None posted |
| Metronidazole250MG ยท tablet;oral | Metronidazole | Rx |
| Metronidazole500MG ยท tablet;oral | Metronidazole | Rx |
| Jul 8, 2024 | Supplement 6Labeling ยท Standard review | Approved | None posted |
| Jun 18, 2024 | Supplement 2Labeling ยท Standard review | Approved | None posted |
| Jun 18, 2024 | Supplement 4Labeling ยท Standard review | Approved | None posted |
| Jun 18, 2024 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Aug 13, 2019 | Supplement 1Labeling ยท Standard review | Approved | None posted |
| Dec 12, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters